Page 1 of 1





A service of the National Library of Medicine and the National Institutes of Health

My NCBI ? [Sign In] [Register]

All Da	tabases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed		for					Pre	eview Go	Clear
		/	~		()	V	`		
		✓ Limits	Prev	riew/Index	History	Clipboard	Details			

Limits: Publication Date to 2003/12/9

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorials

New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
	Search lymphangiogenesis and tumorigenesis Limits: Publication Date to 2003/12/9	11:17:45	<u>5</u>
<u>#5</u>	Search apelin and antisense	07:46:21	<u>2</u>
<u>#1</u>	Search "apelin antibody"	07:26:51	<u>10</u>

Clear History

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Apr 4 2007 12:47:27

```
Welcome to DialogClassic Web(tm)
 Dialog level 05.17.01D
Last logoff: 28mar07 10:29:23
Logon filel 15apr07 13:28:52
          *** ANNOUNCEMENTS ***
NEW FILES RELEASED
***BIOSIS Previews Archive (File 552)
***BIOSIS Previews 1969-2007 (File 525)
***Engineering Index Backfile (File 988)
***Trademarkscan - South Korea (File 655)
RESUMED UPDATING
***File 141, Reader's Guide Abstracts
RELOADS COMPLETED
***File 5, BIOSIS Previews - archival data added
***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online
DATABASES REMOVED
Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453),
IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus
(File 302).
 >>>For the latest news about Dialog products, services, content<<<
 >>>and events, please visit What's New from Dialog at <<<
 >>>http://www.dialog.com/whatsnew/. You can find news about<<<
>>>a specific database by entering HELP NEWS <file number>.<<
 * * *
File
      1:ERIC 1965-2007/Mar
       (c) format only 2007 Dialog
      Set Items Description
      --- ---- ------
Cost is in DialUnits
B 155, 159, 10, 203, 35, 5, 467, 73, 434, 34
       15apr07 13:29:33 User290558 Session D102.1
            $0.98
                   0.279 DialUnits Filel
     $0.98 Estimated cost File1
     $0.18 INTERNET
     $1.16 Estimated cost this search
     $1.16 Estimated total session cost
                                          0.279 DialUnits
SYSTEM:OS - DIALOG OneSearch
  File 155:MEDLINE(R) 1950-2007/Apr 13
         (c) format only 2007 Dialog
  File 159: Cancerlit 1975-2002/Oct
         (c) format only 2002 Dialog
 *File 159: Cancerlit is no longer updating.
Please see HELP NEWS159.
  File 10:AGRICOLA 70-2007/Apr
         (c) format only 2007 Dialog
  File 203:AGRIS 1974-2007/Jan
         Dist by NAL, Intl Copr. All rights reserved
  File 35:Dissertation Abs Online 1861-2007/Mar
```

```
(c) 2007 ProQuest Info&Learning
        5:Biosis Previews(R) 1926-2007/Apr W1
        (c) 2007 The Thomson Corporation
        5: BIOSIS has been enhanced with archival data. Please see
*File
HELP NEWS 5 for information.
 File 467:ExtraMED(tm) 2000/Dec
        (c) 2001 Informania Ltd.
 File 73:EMBASE 1974-2007/Apr 11
        (c) 2007 Elsevier B.V.
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
        (c) 2006 The Thomson Corp
 File 34:SciSearch(R) Cited Ref Sci 1990-2007/Apr W2
        (c) 2007 The Thomson Corp
     Set Items Description
      ___ -----
?
S ANGIOGENESIS AND APELIN
         159120 ANGIOGENESIS
            648 APELIN
             24 ANGIOGENESIS AND APELIN
     S1
S S1 AND ANTIBODY
             24 S1
        1836405 ANTIBODY
             0 S1 AND ANTIBODY
?
       Items Description
Set
               ANGIOGENESIS AND APELIN
S1
          24
               S1 AND ANTIBODY
S2
          0
RD S1
     S3
             14 RD S1 (unique items)
S S3 AND (ANTAGONIST OR INHIBITOR)
             14 S3
         695516 ANTAGONIST
        1661159 INHIBITOR
             2 S3 AND (ANTAGONIST OR INHIBITOR)
?
RD S4
     S5
              2 RD S4 (unique items)
TYPE S5/FULL/1-2
           (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.
18619910
          BIOSIS NO.: 200510314410
The Kruppel-like factor KLF2 is a novel inhibitor of angiogenesis via
repression of the VEGF receptor VEGFR2 (KDR/flk-1)
```

AUTHOR: SenBanerjee Sucharita (Reprint); Bhattacharya Resham; Wang Ping;
Lin Zhiyong; Mukhopadhyay Debabrata; Jain Mukesh K
AUTHOR ADDRESS: Harvard Univ, Brigham and Womens Hosp, Sch Med, Boston, MA
02115 USA**USA

JOURNAL: Circulation 110 (17, Suppl. S): p173 OCT 26 2004 2004

CONFERENCE/MEETING: 77th Scientific Meeting of the
American-Heart-Association New Orleans, LA, USA November 07 -10, 2004;
20041107

SPONSOR: Amer Heart Assoc
ISSN: 0009-7322

DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: The vascular endothelial growth factor (VEGF) receptor - VEGFR2 (KDR/flk-1) - is the major mediator of the mitogenic and angiogenic effects of VEGF. Studies from our laboratory implicate the transcription factor Kruppel-like factor-2 (KLF2) as a key regulator of endothelial function. In this study we provide evidence that KLF2 regulates VEGFR2 expression and, as a consequence, VEGF mediated angiogenesis. Methods and Results: Adenoviral overexpression of KLF2 (Ad-K2) in HUVEC strongly inhibited VEGFR2 (but not VEGFR1) mRNA and protein. Consistent with the reduction of VEGFR2 expression, VEGF mediated calcium mobilization and induction of 3[H]-thymidine uptake were strongly attenuated in KLF2 overexpressing cells. Furthermore, the importance of KLF2 as a regulator of VEGFR2 was verified by siRNA mediated knockdown studies that revealed an induction in basal VEGFR2 expression in HUVEC. To determine the molecular basis for KLF2-mediated inhibition of VEGR2, a series of promoter deletion and mutational analyses were undertaken. These studies demonstrate that KLF2 potently inhibits the VEGFR2 promoter (similar to 70%, p< 0.001) and localize this inhibitory effect to the proximal promoter region. Finally, to assess the functional consequences of KLF2's inhibition of VEGFR2, we injected Ad-VEGF(164) into the ears of athymic mice in the presence or absence of a control adenovirus (Ad-Ctrl)) or Ad-K2. In contrast to control adenovirus, KLF2 overexpression resulted in a marked reduction in vessel formation, CD34+ endothelial staining (see figure below), and tissue edema. Conclusion: These observations identify KLF2 as a novel inhibitor of VEGFR2 and angiogenesis. [GRAPHICS] vitro assays showing that apelin stimulates microvascular endothelial cell migration and proliferation. Conclusion: We conclude from these experiments that (1) apelin is a novel potent angiogenetic factor, (2) the apelin effect on angiogenesis may be mediated via PLC, PI3-kinase and eNOS signaling pathways, and (13) these data add to the profile of apelin/APJ signaling in the regulation of processes that impact tissue perfusion.

REGISTRY NUMBERS: 7440-70-2: calcium; 127464-60-2: vascular endothelial growth factor

DESCRIPTORS:

MAJOR CONCEPTS: Cardiovascular System--Transport and Circulation

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: HUVEC cell line (Hominidae)

COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates; Vertebrates

CHEMICALS & BIOCHEMICALS: calcium; vascular endothelial growth factor {

VEGF}; Kruppel-like factor 2 {KKLF2}; vascular endothelial growth factor receptor 2 {flk-1}--expression

MISCELLANEOUS TERMS: angiogenesis; vessel formation; Meeting Abstract

CONCEPT CODES:

```
00520 General biology - Symposia, transactions and proceedings 02508 Cytology - Human 10064 Biochemistry studies - Proteins, peptides and amino acids 10069 Biochemistry studies - Minerals 14504 Cardiovascular system - Physiology and biochemistry 17002 Endocrine - General BIOSYSTEMATIC CODES: 86215 Hominidae
```

5/9/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18619909 BIOSIS NO.: 200510314409
The cardiovascular regulator apelin is an angiogenic factor in vivo

AUTHOR: Kundu Ramendra K (Reprint); Eichhorn Jens; Chen Mary; Ho Yen-Dong; Ashley Euan; Varner Judith; Kuo Calvin; Quertermous Thomas AUTHOR ADDRESS: Stanford Univ, Palo Alto, CA 94304 USA**USA JOURNAL: Circulation 110 (17, Suppl. S): p173 OCT 26 2004 2004 CONFERENCE/MEETING: 77th Scientific Meeting of the American-Heart-Association New Orleans, LA, USA November 07 -10, 2004; 20041107

SPONSOR: Amer Heart Assoc

ISSN: 0009-7322

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: Objective: Given the embryonic endothelial cell-specific pattern of expression for the high affinity apelin receptor, APJ, we have employed and established in vivo assays to investigate the angiogenic potential of this signaling pathway, Methods and Results: In ovo chick chorioallantoic membrane assays, evaluated with vessel branch point counting, apelin-13 revealed a 3-fold maximal increase in angiogenesis that was 141% of the maximal effect of bFGF. In the rabbit cornea assay apelin-13 had a maximal angiogenic effect that was 43% of the maximal effect produced with VEGF. In the in vivo Matrigel assay, evaluated on the basis of hemoglobin content by Drabkin's assay and endothelial morphometry, a 4-fold increase in vascularization with apelin-13 was observed compared to a 5-fold increase with bFGF. To achieve these levels of angiogenesis, 2-10-fold higher molar concentrations of apelin-13 was required, suggesting this form of apelin may not be the most potent isoform for stimulating angiogenesis. To investigate signaling pathways that may mediate the apelin-induced angiogenesis, in vivo Matrigel assays were performed in the presence of pharmaceutical inhibitors. Inhibition of angiogenesis was observed for some inhibitors, including the PLC inhibitor U73122 (90% inhibition), eNOS inhibitor L-NAME (78% inhibition), and PI3-kinase inhibitor Wortmannin (90% inhibition) to the Matrigel plugs resulted in a significant decrease in apelin-Induced angiogenesis. The control inhibitor compound U73343 had no effect. These findings were confirmed in an in vitro Matrigel assay using human lung microvascular endothelial cells. Also, the in vivo angiogenesis assays were supported by in vitro assays showing that apelin stimulates microvascular endothelial cell migration and proliferation. Conclusion: We conclude from these experiments that (1) apelin is a novel potent angiogenetic factor, (2) the apelin effect on angiogenesis may be mediated via PLC, PI3-kinase and eNOS signaling pathways, and (13) these data add to the profile of apelin/APJ signaling in the regulation of processes that impact tissue perfusion.

```
REGISTRY NUMBERS: 19545-26-7: wortmannin; 112648-68-7: U73122; 50903-99-6:
    L-NAME; 217082-58-1: apelin-13; 372170-33-7: apelin
DESCRIPTORS:
  MAJOR CONCEPTS: Cardiovascular System--Transport and Circulation
  BIOSYSTEMATIC NAMES: Galliformes--Aves, Vertebrata, Chordata, Animalia;
    Leporidae--Lagomorpha, Mammalia, Vertebrata, Chordata, Animalia
  ORGANISMS: chicken (Galliformes); rabbit (Leporidae)
  ORGANISMS: PARTS ETC: cornea--sensory system; chorioallantoic membrane--
    embryonic structure; lung microvascular endothelial cell--circulatory
    system, respiratory system
  COMMON TAXONOMIC TERMS: Birds; Animals; Chordates; Lagomorphs; Mammals;
    Nonhuman Vertebrates; Nonhuman Mammals; Vertebrates
                              wortmannin--enzyme inhibitor-drug; U73122--
  CHEMICALS & BIOCHEMICALS:
    enzyme inhibitor-drug; PLC {phospholipase C}; eNOS {endothelial nitric
    oxide synthase); PI3-kinase; L-NAME {N-G-nitro-L-arginine methyl ester}
    --enzyme inhibitor-drug; apelin-13; apelin--angiogenic factor,
    cardiovascular regulator
  MISCELLANEOUS TERMS: cell proliferation; cell migration; Meeting
   Abstract
CONCEPT CODES:
  00520 General biology - Symposia, transactions and proceedings
  02506 Cytology - Animal
  10064 Biochemistry studies - Proteins, peptides and amino acids
  10068 Biochemistry studies - Carbohydrates
  10802 Enzymes - General and comparative studies: coenzymes
  14504 Cardiovascular system - Physiology and biochemistry
  16004 Respiratory system - Physiology and biochemistry
  20004 Sense organs - Physiology and biochemistry
  25502 Development and Embryology - General and descriptive
BIOSYSTEMATIC CODES:
  85536 Galliformes
  86040 Leporidae
```